Wednesday, 31 May 2017

Detailed Research on Japan Market for Pelvic Organ Prolapse Repair 2017

Japan Market Report for Pelvic Organ Prolapse Repair 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The primary driver of growth for this device market is an increase in procedure numbers, driven by an aging female demographic. However, in 2012 there was a sharp decline in procedures triggered by reports of negative and serious side effects including numerous litigations surrounding the vaginal mesh market. The majority of the concern was about transvaginal mesh. Overall, the combination of these factors has led to a stable market overall with a small growth in unit sales expected over the forecast period. 
The market has begun and is expected to continue a substantial shift from transvaginal mesh to sacrocolpopexy mesh. While transvaginal mesh sales currently comprise the majority of the market, their dominance will decrease as physicians move towards sacrocolpopexy mesh at increasing rates. While the FDA warnings issued in 2011 had the greatest effect on the United States market, the Japanese market was also impacted. Modifications to the mesh, extra clinical trials to prove safety and pre-emptive marketing is helping to clarify the safety and health risks associated with mesh to curb the decline in procedures. 
Even though the transvaginal mesh market is declining, a smaller but solid demand for this product will remain over the forecast period. ASPs for both types of mesh have been relatively stable, with a slight decline on average over the past few years. Changes in the market due to companies choosing to leave the market, notably Johnson & Johnson’s transvaginal mesh products, have created a competitive market environment as market share is reallocated. Combined with recovering unit sales, there is a high incentive to increase affordability and help procedure numbers recover through stable prices.
Companies Mentioned
Kitazato Cook Medical Olympus Cooper Surgical Boston Scientific Vitrolife Irvine Scientific Naka Medical Johnson & Johnson Karl Storz Vitromed Rocket Medical Medi-Con International Carl Zeiss Sankyo Medical Pentax Life Global (IVF Online) Astec Bio The Pipette Company Esco Global Stryker Richard Wolf Merit Medical Systems BTG Leica Medtronic Others include: Nidacon Medical, Reproline Medical, ThermoFisher, AngioDynamics, Welch Allyn, local competitors, etc.
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research

No comments:

Post a Comment